United States — Food and Drug Administration & Kahn Swick & Foti

United States — Food and Drug Administration: The United States — Food and Drug Administration issued a warning letter to ImmunityBio regarding misleading efficacy claims made by Patrick Soon-Shiong about Anktiva, which triggered the stock price drop and subsequent lawsuits.

Kahn Swick & Foti: Kahn Swick & Foti is a law firm that has also filed a securities class action lawsuit against ImmunityBio, representing investors who suffered losses.

United States — Food and Drug Administration: The FDA published briefing documents critical of Capricor's statistical analysis plan and raised concerns about the benefit-risk profile of Deramiocel. This regulatory action triggered the stock drop and the subsequent lawsuit, and it may influence the advisory committee's decision on the BLA.

Kahn Swick & Foti: Kahn Swick & Foti is the law firm representing investors in the class action lawsuit against Capricor. The firm benefits from the case through potential legal fees and settlements, and its reputation is enhanced by pursuing securities litigation.

United States — Food and Drug Administration: Regulator whose briefing documents and advisory committee vote triggered the stock collapse and legal actions.

Kahn Swick & Foti: Filed a class action lawsuit against Capricor.